Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, primarily due to channel optimization and increased promotional expenses [1] Financial Performance - The company achieved operating revenue of 863 million yuan, a year-on-year decrease of 8.15% [1] - The net profit attributable to shareholders was 230 million yuan, down 32.54% year-on-year [1] - The net profit excluding non-recurring gains and losses was 166 million yuan, a decrease of 48.66% year-on-year [1] - Basic earnings per share were 0.44 yuan [1] Product and Sales Strategy - The product matrix includes medical devices and functional skincare products, covering various forms such as masks, serums, and lotions [1] - The company employs a multi-channel sales strategy, integrating online and offline channels, with online sales covering major platforms like Tmall, Douyin, JD.com, and Pinduoduo [1] - Offline sales include medical institutions, beauty institutions, retail pharmacies, specialty cosmetics stores, and large supermarkets [1] - The company has developed several star products with annual sales exceeding 100 million yuan, such as medical sodium hyaluronate repair patches [1] Revenue Channel Breakdown - In the online channel, direct sales accounted for 62.12%, while distribution and agency sales made up 18.38% [2] - In the offline channel, direct sales and distribution accounted for 0.11% and 19.39%, respectively [2] R&D and Innovation - The company adopts a collaborative R&D model to quickly adapt to industry technology iterations and enhance research capabilities [2] - It focuses on basic research in raw materials and strengthens partnerships with research institutions to drive innovation [2] - The company has established dual R&D centers in Shanghai and Harbin to bolster its research capabilities [2] - As of June 30, 2025, the company has obtained 31 patents, including 9 invention patents [3] - The company plans to continue focusing on its core business, increasing R&D efforts, and enhancing its product line in the medical device and cosmetics sectors [3]